https://orcid.org/0000-0002-3411-6357
References
- Robak P, Robak T. Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages. Expert Opin Biol Ther. 2023;23(1):21–35.
- Goede V, Fischer K, Dyer MJ, et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. In Proceedings from the European Hematology Association Annual Meeting; June 2018; Stockholm, Sweden (Abstract S151).
- Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756–1765.
- Eichhorst B, Fink AM, Bahlo J, German CLL Study Group (GCLLSG), et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open -label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–942.
- Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the german chronic lymphocytic leukemia study group. J Clin Oncol. 2011;29(26):3559–3566.
- Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2021;32(1):23–33.
- Bravo J, Baltasar Tello P, González Garcia E, et al. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study. Leuk Lymphoma. 2023; (in press).
- Stilgenbauer S, Bosch F, Ilhan O, et al. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: final analysis of the phase IIIb GREEN study. Br J Haematol. 2021;193(2):325–338.
- Kutsch N, Holmes EE, Robrecht S, et al. Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (G-FC) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients. Leuk Lymphoma. 2023;64(2):478–482.
- Seymour JF, Kipps TJ, Eichhorst BF, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140(8):839–850.
- Byrd JC, Brown JR, O'Brien S, RESONATE Investigators, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
- Hansson L, Asklid A, Diels J, et al. Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia. Ann Hematol. 2017;96(10):1681–1691.
- Cuneo A, Follows G, Rigolin GM, GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL Forum, et al. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018;103(7):1209–1217.
- Hillmen P, Fraser G, Jones J, et al. Comparing single agent ibrutinib, bendamustine plus rituximab (BR) and ibrutinib plus BR in patients with previously treated chronic lymphocytic leukemia/small lymphocytic ymphoma (CLL/SLL): an indirect comparison of the RESONATE and HELIOS trials [abstract]. 57th ASH Annual Meeting; 2015 December 5–8; Orlando, FL (Abstract 2944).
- Ghia P, Pluta A, Wach M, et al. Acalabrutinib versus investigator’s choice in relapsed/refractory chronic lymphocytic leukemia: final ASCEND trial results. Hemasphere. 2022;6(12):e801.